Neurodegenerative and cerebrovascular diseases are frequent in elderly populations and comprise primarily of dementia (mainly Alzheimer disease (AD)), Parkinson disease (PD) and stroke. The prevalence of these neurological disorders rises with older age. From 55 years to 90 years and above, the prevalence of dementia increases from less than 1% to over 40%.1-3 For PD, the prevalence increases over the same age range from less than 0.5% to more than 4%,4,5 and for stroke from approximately 1% to nearly 10%.6,7 Similar age-related patterns are observed for incidence figures.8-11 In the Netherlands, the population of persons of 65 years and older is expected to increase from 2.4 million in 2007 to 3.9 million in 2050.12 At a global level, 2 billion persons above 65 years are expected by 2050.13 As a consequence of the aging population the incidence and prevalence of age-related neurological diseases will increase accordingly. Moreover, these neurological disorders all constitute highly disabling diseases, with appreciable impact on quality-of-life at the patient level, but also on society, both economically and socially.12,14-17 Currently, there is no effective cure for AD18, PD19 or the consequences of stroke.20 Hence, identification of determinants of these neurological diseases and development of preventive strategies is of paramount importance. This search is, in part, directed at currently available drugs which target established risk factors of neurological disease, or that have, in in vivo or in vitro studies, shown to interfere with more specific elements of the supposed pathogenic pathway of disease. Two drug groups commonly used by elderly are of interest, namely nonsteroidal anti-inflammatory drugs (NSAIDs) and cardiovascular medication. The general objective of this thesis was to study the role of these drugs as determinants of neurodegenerative and cerebrovascular diseases.

, ,
The publication of this thesis was financially supported by the Department of Epidemiology at Erasmus MC and Erasmus University, Rotterdam, the Netherlands. Addtional financial support for publication of this thesis was granted by: Alzheimer NederlandAstraZenecaInternationale Stichting Alzheimer OnderzoekPfizer bv.
B.H.Ch. Stricker (Bruno) , M.M.B. Breteler (Monique)
Erasmus University Rotterdam
Erasmus MC: University Medical Center Rotterdam

Haag, M. (2009, February 13). NSAIDs and cardiovascular drugs in neurodegenerative and cerebrovascular diseases. Retrieved from